CD8A and cancer: Immunotherapy includes ICI that revitalizes dysfunctional T cells, adoptive cell transfer using CD8+ T cells equipped with synthetic chimeric antigen receptors (CAR-T) that enhance T cell functionality, and antibody-based therapies targeting cancer-specific antigens.